Tags

Type your tag names separated by a space and hit enter

Risk and predictors of mortality associated with chronic hepatitis B infection.
Clin Gastroenterol Hepatol. 2007 Aug; 5(8):921-31.CG

Abstract

BACKGROUND & AIMS

The study objective was to determine the risk of all-cause and cause-specific mortality as well as to examine the predictors of mortality in chronic hepatitis B infection.

METHODS

We performed a prospective cohort study of 23,820 persons (age, 30-65 y) recruited between 1991 and 1992 and followed up through 2004 from 7 townships in Taiwan. The main outcomes were all-cause and liver-related mortality rates. Mortality analyses used time-to-events methods, and survival curves were derived by the Kaplan-Meier method. Cox proportional hazard models were used to estimate multivariable-adjusted hazard ratios.

RESULTS

There were 1814 deaths during a mean follow-up period of 12.5 years (282,323.7 person-years of follow-up evaluation). Persons positive for hepatitis B surface antigen (HBsAg) had significantly (P < .01) higher adjusted hazard ratios for all causes of mortality (1.7; 95% confidence interval [CI], 1.5-1.9), liver cancer mortality (22.4; 95% CI, 15.2-32.9), and chronic liver disease and cirrhosis mortality (5.4; 95% CI, 3.5-8.4). When compared with HBsAg-negative persons, hepatitis B virus (HBV)-infected persons with HBV DNA levels less than 10(4) had a high risk of hepatocellular carcinoma mortality (4.4; 95% CI, 2.4-8.2). In HBsAg-positive persons, the mortality rate increased with cohort entry serum HBV DNA level. Liver cancer mortality ranged from 72.8 per 100,000 person-years for subjects with HBV DNA levels less than 300 copies/mL to 815.6 per 100,000 person-years for those with HBV DNA levels of 1 million copies/mL or greater. Chronic liver disease and cirrhosis deaths ranged from 9.1 to 267.4 per 100,000 person-years.

CONCLUSIONS

Chronic HBV infection is associated with significant preventable excess mortality risk. This mortality risk is correlated strongly with the level of viral replication among other factors.

Authors+Show Affiliations

Global Epidemiology and Outcomes Research, Pharmaceutical Research Institute, Bristol-Myers Squibb Company Wallington, Connecticut, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17678844

Citation

Iloeje, Uchenna H., et al. "Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection." Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association, vol. 5, no. 8, 2007, pp. 921-31.
Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5(8):921-31.
Iloeje, U. H., Yang, H. I., Jen, C. L., Su, J., Wang, L. Y., You, S. L., & Chen, C. J. (2007). Risk and predictors of mortality associated with chronic hepatitis B infection. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association, 5(8), 921-31.
Iloeje UH, et al. Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection. Clin Gastroenterol Hepatol. 2007;5(8):921-31. PubMed PMID: 17678844.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk and predictors of mortality associated with chronic hepatitis B infection. AU - Iloeje,Uchenna H, AU - Yang,Hwai-I, AU - Jen,Chin-Lan, AU - Su,Jun, AU - Wang,Li-Yu, AU - You,San-Lin, AU - Chen,Chien-Jen, AU - ,, PY - 2007/8/7/pubmed PY - 2007/12/6/medline PY - 2007/8/7/entrez SP - 921 EP - 31 JF - Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association JO - Clin Gastroenterol Hepatol VL - 5 IS - 8 N2 - BACKGROUND & AIMS: The study objective was to determine the risk of all-cause and cause-specific mortality as well as to examine the predictors of mortality in chronic hepatitis B infection. METHODS: We performed a prospective cohort study of 23,820 persons (age, 30-65 y) recruited between 1991 and 1992 and followed up through 2004 from 7 townships in Taiwan. The main outcomes were all-cause and liver-related mortality rates. Mortality analyses used time-to-events methods, and survival curves were derived by the Kaplan-Meier method. Cox proportional hazard models were used to estimate multivariable-adjusted hazard ratios. RESULTS: There were 1814 deaths during a mean follow-up period of 12.5 years (282,323.7 person-years of follow-up evaluation). Persons positive for hepatitis B surface antigen (HBsAg) had significantly (P < .01) higher adjusted hazard ratios for all causes of mortality (1.7; 95% confidence interval [CI], 1.5-1.9), liver cancer mortality (22.4; 95% CI, 15.2-32.9), and chronic liver disease and cirrhosis mortality (5.4; 95% CI, 3.5-8.4). When compared with HBsAg-negative persons, hepatitis B virus (HBV)-infected persons with HBV DNA levels less than 10(4) had a high risk of hepatocellular carcinoma mortality (4.4; 95% CI, 2.4-8.2). In HBsAg-positive persons, the mortality rate increased with cohort entry serum HBV DNA level. Liver cancer mortality ranged from 72.8 per 100,000 person-years for subjects with HBV DNA levels less than 300 copies/mL to 815.6 per 100,000 person-years for those with HBV DNA levels of 1 million copies/mL or greater. Chronic liver disease and cirrhosis deaths ranged from 9.1 to 267.4 per 100,000 person-years. CONCLUSIONS: Chronic HBV infection is associated with significant preventable excess mortality risk. This mortality risk is correlated strongly with the level of viral replication among other factors. SN - 1542-7714 UR - https://www.unboundmedicine.com/medline/citation/17678844/Risk_and_predictors_of_mortality_associated_with_chronic_hepatitis_B_infection_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1542-3565(07)00631-3 DB - PRIME DP - Unbound Medicine ER -